Bildkälla: Stockfoto

Cantargia Q4 2023: Progress with CAN10 and in PDAC - Redeye

Redeye comments on Cantargia's Q4 report, which contains progress with CAN10 and with nadunolimab in pancreatic cancer, now ready for a phase IIb trial.

Redeye comments on Cantargia's Q4 report, which contains progress with CAN10 and with nadunolimab in pancreatic cancer, now ready for a phase IIb trial.
Börsvärldens nyhetsbrev
ANNONSER